Abstract
The results of this study show that during growth of the immunogenic Meth A fibrosarcoma, two different types of suppressor T lymphocytes are generated in sequence. One type is generated during early tumor growth, reaches peak number around day 6, and is progressively lost thereafter. It is defined by its ability, upon passive transfer, to suppress the expression of a DTH reaction to tumor antigens in tumor- immunized recipients. It bears the Ly1-,2+ membrane phenotype and is sensitive to relatively low doses of cyclophosphamide. In contrast, the second type of suppressor cell is not detected until after day 9 of tumor growth, and is defined by its ability to inhibit, upon passive transfer, the expression of adoptive immunity against an established tumor in T cell-deficient recipients. According to previous studies it bears the Ly1+,2-, L3T4a+ membrane phenotype and is less sensitive to cyclophosphamide than the T cell suppressor of DTH. It is argued that this second type of suppressor T cell seems likely to be responsible for the escape of immunogenic tumors from antitumor immunity, because it can suppress the expression of a powerful mechanism of antitumor immunity in recipient mice, and is generated progressively as the tumor- bearing host loses concomitant immunity. In contrast, although the Ly-1- ,2+ T cell suppressors of DTH can efficiently suppress a DTH reaction to an implant of living tumor cells, they fail to suppress the expression of immunity to the same implant.
Full Text
The Full Text of this article is available as a PDF (794.2 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Berendt M. J., North R. J. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med. 1980 Jan 1;151(1):69–80. doi: 10.1084/jem.151.1.69. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dialynas D. P., Quan Z. S., Wall K. A., Pierres A., Quintáns J., Loken M. R., Pierres M., Fitch F. W. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule. J Immunol. 1983 Nov;131(5):2445–2451. [PubMed] [Google Scholar]
- Dye E. S., North R. J., Mills C. D. Mechanisms of anti-tumor action of Corynebacterium parvum. I. Potentiated tumor-specific immunity and its therapeutic limitations. J Exp Med. 1981 Sep 1;154(3):609–620. doi: 10.1084/jem.154.3.609. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dye E. S., North R. J. Specificity of the T cells that mediate and suppress adoptive immunotherapy of established tumors. J Leukoc Biol. 1984 Jul;36(1):27–37. doi: 10.1002/jlb.36.1.27. [DOI] [PubMed] [Google Scholar]
- Dye E. S., North R. J. T cell-mediated immunosuppression as an obstacle to adoptive immunotherapy of the P815 mastocytoma and its metastases. J Exp Med. 1981 Oct 1;154(4):1033–1042. doi: 10.1084/jem.154.4.1033. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Fujimoto S., Greene M. I., Sehon A. H. Regualtion of the immune response to tumor antigens. I. Immunosuppressor cells in tumor-bearing hosts. J Immunol. 1976 Mar;116(3):791–799. [PubMed] [Google Scholar]
- Greene M. I. The genetic and cellular basis of regulation of the immune response to tumor antigens. Contemp Top Immunobiol. 1980;11:81–116. doi: 10.1007/978-1-4684-3701-0_2. [DOI] [PubMed] [Google Scholar]
- Hall B. M., Jelbart M. E., Gurley K. E., Dorsch S. E. Specific unresponsiveness in rats with prolonged cardiac allograft survival after treatment with cyclosporine. Mediation of specific suppression by T helper/inducer cells. J Exp Med. 1985 Nov 1;162(5):1683–1694. doi: 10.1084/jem.162.5.1683. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Hawrylko E., Mele C. A., Stutman O. Tumor bearer T cells suppress BCG-potentiated antitumor responses II. Characteristics of the efferent phase suppressor. Cell Immunol. 1982 Jan 1;66(1):139–151. doi: 10.1016/0008-8749(82)90164-2. [DOI] [PubMed] [Google Scholar]
- Hawrylko E. Tumor bearer T cells suppress BCG-potentiated antitumor responses. I. Requirements for their effect. Cell Immunol. 1982 Jan 1;66(1):121–138. doi: 10.1016/0008-8749(82)90163-0. [DOI] [PubMed] [Google Scholar]
- Mullen C. A., Urban J. L., Van Waes C., Rowley D. A., Schreiber H. Multiple cancers. Tumor burden permits the outgrowth of other cancers. J Exp Med. 1985 Nov 1;162(5):1665–1682. doi: 10.1084/jem.162.5.1665. [DOI] [PMC free article] [PubMed] [Google Scholar]
- North R. J., Bursuker I. Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J Exp Med. 1984 May 1;159(5):1295–1311. doi: 10.1084/jem.159.5.1295. [DOI] [PMC free article] [PubMed] [Google Scholar]
- North R. J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med. 1982 Apr 1;155(4):1063–1074. doi: 10.1084/jem.155.4.1063. [DOI] [PMC free article] [PubMed] [Google Scholar]
- North R. J. Down-regulation of the antitumor immune response. Adv Cancer Res. 1985;45:1–43. doi: 10.1016/s0065-230x(08)60265-1. [DOI] [PubMed] [Google Scholar]
- North R. J., Dye E. S. Ly 1+2- suppressor T cells down-regulate the generation of Ly 1-2+ effector T cells during progressive growth of the P815 mastocytoma. Immunology. 1985 Jan;54(1):47–56. [PMC free article] [PubMed] [Google Scholar]
- Ullrich S. E., Kripke M. L. Mechanisms in the suppression of tumor rejection produced in mice by repeated UV irradiation. J Immunol. 1984 Nov;133(5):2786–2790. [PubMed] [Google Scholar]